^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lipoplatin (cisplatin liposomal)

    Associations

    News

    Trials
    Company:
    Regulon
    Drug class:
    DNA cross linking agent
    Related drugs:
    Associations

    News

    Trials
    2ms
    Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation. (PubMed, ACS Appl Mater Interfaces)
    Importantly, αPD-L1@Lipoplatin effectively suppresses tumor growth without causing significant hepatorenal toxicity, maintaining stable body weight and showing no histopathological abnormalities in major organs. This feedback-amplified drug delivery system offers a promising strategy to enhance drug delivery efficiency and αPD-L1 responsiveness, holding great potential for improving NSCLC immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    PD-L1 expression
    |
    Lipoplatin (cisplatin liposomal)
    3years
    Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model. (PubMed, J Int Adv Otol)
    For the treatment of neuroblastoma, the use of lipoplatin seems to be beneficial in reducing side effects of cisplatin. We recommend that the mechanism of these properties of lipoplatin should be evaluated in further studies.
    Preclinical • Journal
    |
    NOS2 (Nitric Oxide Synthase 2) • SOD2 (Superoxide Dismutase 2)
    |
    PTGS2 mutation
    |
    Lipoplatin (cisplatin liposomal)